Project Grant R21CA292755
Award Date
9/6/24
Completion Date
8/31/26
Dollars Obligated
$476K
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Boston, MA 02115, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $627,474 to the Dana-Farber Cancer Institute to conduct research aimed at leveraging innovative epigenomic methods and signatures to inform the understanding of prostate cancer lineage plasticity, including treatment-emergent neuroendocrine prostate cancer (NEPC). The key goals are to utilize epigenomic signatures to detect NEPC and predict enzalutamide resistance, as well...
This $649,486 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cedars-Sinai Medical Center aims to develop an innovative, minimally invasive liquid biopsy assay that can identify molecular subtypes of lethal prostate cancer. The key objectives are to: Perform analytical validation of technologies for isolating large oncosomes (LO) from patient plasma samples for clinical use. Develop a multianalyte LO-based assay to detect lethal...
This federal Project Grant award for $538,553, provided by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), will support research to define the role of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The 5-year project, which commenced on April 1, 2025, will be conducted by the University...
This $704,882 Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), aims to define the genetic factors underlying familial prostate cancer (PCA) in African American (AA) men and develop a risk prediction tool for PCA in the AA population. The research will leverage existing genetic data from over 24,000 unselected AA PCA cases and controls, including the landmark RESPOND cohort, to: Enroll additional eligible first-...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), will support research conducted by Thomas Jefferson University to investigate genomic factors contributing to racial disparities in metastatic prostate cancer outcomes. The key products or services to be delivered under this $156,000 award include whole-exome sequencing of circulating tumor cells (CTCs) from paired Black and White patients with metastatic...
This federal Project Grant award in the amount of $1,229,700.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award is supporting research conducted by the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, Massachusetts focused on "DISSECTION OF MOLECULAR ASSOCIATIONS OF RESPONSE TO NEOADJUVANT ANTIANDROGEN THERAPIES IN HIGH-RISK LOCALIZED PROSTATE CANCER." The 4-year research project aims to advance the...
This $2,136,715 Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) is focused on harnessing DNA methylation in peripheral blood to improve colorectal cancer prevention. The primary awardee, President and Fellows of Harvard College through its Harvard T.H. Chan School of Public Health, will lead the research effort. Key sub-awards have been made to Dana-Farber Cancer Institute and Boston University to contribute...
The National Cancer Institute awarded a Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) totaling $568,151 to the Regents of the University of Michigan. The grant will fund research to develop a real-time functional photoacoustic imaging platform with the capability to quantitatively evaluate prostate cancer tumor heterogeneity and microenvironment for improved prostate cancer diagnosis and prognosis. The research aims to optimize photoacoustic-nanoparticle contrast...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Cause and Prevention Research program (CFDA 93.393), provides $577,529 to Health Research, Inc. to investigate the relationship between accelerated ribosomal DNA (rDNA) methylation age and early-onset prostate cancer in African American patients. The main objectives are to: 1) determine if African American prostate cancer patients exhibit higher rDNA methylation age at diagnosis compared to age-matched...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,902.00 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key research objectives are to determine if expression of the FOXA2 transcription factor drives prostate cancer cells into a multilineage transition state, investigate how FOXA2 collaborates with the AP-1...